Back to Journals » Clinical Ophthalmology » Volume 7
Diabetic papillopathy with macular edema treated with intravitreal ranibizumab
Authors Kim M, Lee J, Lee SJ, Han SB
Received 27 September 2013
Accepted for publication 17 October 2013
Published 27 November 2013 Volume 2013:7 Pages 2257—2260
DOI https://doi.org/10.2147/OPTH.S55076
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Moosang Kim,* Jang-Hun Lee,* Seung-Jun Lee
Department of Ophthalmology, Kangwon National University, Chuncheon, South Korea
*These authors contributed equally to this work
Abstract: We report a case of diabetic papillopathy that demonstrated a resolution of optic disk swelling and rapid visual recovery when intravitreal ranibizumab was administered. A 51-year-old male presented with acute painless visual loss in his right eye. His vision was 20/320 in the right eye and 20/50 in the left eye. Fundus examination of the right eye showed nonproliferative diabetic retinopathy with macular edema and a swollen optic disk. Fluorescein angiography showed dye leakage from the right optic disk. Optical coherent tomography revealed a significant increase in retinal nerve fiber-layer thickness. Magnetic resonance imaging of the brain was normal. The patient received a single intravitreal ranibizumab (0.5 mg) injection. Two weeks following injection, there was marked regression of the disk swelling and improvement of macular edema, with vision improving to 20/100. Three months following injection, there was complete resolution of the optic disk swelling. No further treatment was required.
Keywords: diabetic papillopathy, optic disk swelling, ranibizumab
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.